These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12190194)

  • 21. Toward improved adverse event/suspected adverse drug reaction reporting.
    Gross R; Strom BL
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
    [No Abstract]   [Full Text] [Related]  

  • 22. Venous sclerosants: distant ischaemic disorders.
    Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682017
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA-approved sodium tetradecyl sulfate (STS) versus compounded STS for venous sclerotherapy.
    Almeida JI; Raines JK
    Dermatol Surg; 2007 Sep; 33(9):1037-44; discussion 1044. PubMed ID: 17760594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MedWatch: the new medical products reporting program.
    Couig MP; Merkatz RB
    Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839
    [No Abstract]   [Full Text] [Related]  

  • 25. Chronic facial pain following injection of sodium tetradecyl sulphate into an intraparotid haemolymphangioma.
    Crampsey DP; Cochrane L; Roebuck D; Hartley BE
    J Laryngol Otol; 2008 Sep; 122(9):1002-4. PubMed ID: 17625033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. More on hypertrichosis after sclerotherapy.
    Kiripolsky MG
    Dermatol Surg; 2010 Jun; 36 Suppl 2():1066-7. PubMed ID: 20590715
    [No Abstract]   [Full Text] [Related]  

  • 27. Adverse drug effects: new information about an old problem.
    Miller CA
    Geriatr Nurs; 2001; 22(6):336-7. PubMed ID: 11780009
    [No Abstract]   [Full Text] [Related]  

  • 28. Post-marketing surveillance and adverse drug reactions.
    Shani S
    Isr Med Assoc J; 1999 Oct; 1(2):117-9. PubMed ID: 10731310
    [No Abstract]   [Full Text] [Related]  

  • 29. Nefazodone- and/or sodium tetradecyl sulfate-associated leukopenia, fever, and shaking chills in a patient with premenstrual dysphoric disorder.
    Fogelson DL
    J Clin Psychopharmacol; 1997 Jun; 17(3):222-3. PubMed ID: 9169968
    [No Abstract]   [Full Text] [Related]  

  • 30. A report on the use of sotradecol, a new sclerosing agent.
    PIERPONT RZ; BRANTIGAN OC
    Bull Sch Med Univ Md; 1948 Jul; 33(1):1-7. PubMed ID: 18877392
    [No Abstract]   [Full Text] [Related]  

  • 31. Three cases of stroke following peripheral venous interventions.
    Gillet JL
    Phlebology; 2013 Feb; 28(1):55. PubMed ID: 23535707
    [No Abstract]   [Full Text] [Related]  

  • 32. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J; Friedlin J; Ryan P
    Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
    [No Abstract]   [Full Text] [Related]  

  • 33. The drug safety system conundrum.
    Tiedt TN
    Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
    [No Abstract]   [Full Text] [Related]  

  • 34. Inadvertent injection of sodium tetradecyl sulfate during placement of mental nerve block: discussion of management and outcome.
    Kiken DA; Goldman MP
    Dermatol Surg; 2009 Dec; 35(12):2042-5. PubMed ID: 19737289
    [No Abstract]   [Full Text] [Related]  

  • 35. [Severe complication after sclerosing injection for hemorrhoids of sodium tetradecyl sulfate].
    VIGUIE R
    Arch Mal Appar Dig Mal Nutr; 1955; 44(7-8):929-32. PubMed ID: 13276034
    [No Abstract]   [Full Text] [Related]  

  • 36. Consumer groups look to improve adverse event reporting systems.
    Vastag B
    J Natl Cancer Inst; 2005 Dec; 97(24):1804-5. PubMed ID: 16368939
    [No Abstract]   [Full Text] [Related]  

  • 37. Injection sclerotherapy for spider telangiectasias: a 20-year experience with sodium tetradecyl sulfate.
    Tretbar LL
    J Dermatol Surg Oncol; 1989 Feb; 15(2):223-5. PubMed ID: 2915089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmarketing surveillance and reporting of adverse drug events.
    Baer RK
    S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
    [No Abstract]   [Full Text] [Related]  

  • 39. Embolization and endothelial ablation with chitosan and sodium sotradecol sulfate: preliminary results in an animal model.
    Chabrot P; Fatimi A; Fraine PD; Ouchchane L; Dauplat MM; Rivard A; Lerouge S; Soulez G
    J Endovasc Ther; 2012 Jun; 19(3):439-49. PubMed ID: 22788899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The need for a post-marketing surveillance program in Israel.
    Shemer J
    Isr Med Assoc J; 1999 Oct; 1(2):98-9. PubMed ID: 10731306
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.